<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Investig Med High Impact Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">J Investig Med High Impact Case Rep</journal-id><journal-id journal-id-type="publisher-id">HIC</journal-id><journal-id journal-id-type="hwp">sphic</journal-id><journal-title-group><journal-title>Journal of Investigative Medicine High Impact Case Reports</journal-title></journal-title-group><issn pub-type="epub">2324-7096</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1177/2324709620930540</article-id><article-id pub-id-type="publisher-id">10.1177_2324709620930540</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>The Coincidence of 2 Epidemics, Coccidioidomycosis and SARS-CoV-2: A Case
Report</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Amar S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1-2324709620930540">1</xref></contrib><contrib contrib-type="author"><name><surname>Heidari</surname><given-names>Arash</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1-2324709620930540">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1052-0144</contrib-id><name><surname>Civelli</surname><given-names>Valerie F.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1-2324709620930540">1</xref><xref ref-type="corresp" rid="corresp1-2324709620930540"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Ritika</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1-2324709620930540">1</xref></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Charles S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1-2324709620930540">1</xref></contrib><contrib contrib-type="author"><name><surname>Munoz</surname><given-names>Augustine D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1-2324709620930540">1</xref></contrib><contrib contrib-type="author"><name><surname>Ragland</surname><given-names>Alan Scott</given-names></name><degrees>DO</degrees><xref ref-type="aff" rid="aff1-2324709620930540">1</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Royce H.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1-2324709620930540">1</xref></contrib></contrib-group><aff id="aff1-2324709620930540"><label>1</label>UCLA&#x02014;Kern Medical, Bakersfield, CA, USA</aff><author-notes><corresp id="corresp1-2324709620930540">Valerie F. Civelli, MD, Department of Infectious
Disease, UCLA&#x02014;Kern Medical, 1700 Mount Vernon Avenue, Bakersfield, CA 93306, USA. Email:
<email>vcivelli@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>4</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2020</year></pub-date><volume>8</volume><elocation-id>2324709620930540</elocation-id><history><date date-type="received"><day>16</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>28</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 American Federation for Medical Research</copyright-statement><copyright-year>2020</copyright-year><copyright-holder content-type="society">American Federation for Medical
Research</copyright-holder><license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits
non-commercial use, reproduction and distribution of the work without further permission
provided the original work is attributed as specified on the SAGE and Open Access pages
(<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>In the middle of a pandemic, patients with cough and fever are thought to have SARS-CoV-2
(severe acute respiratory syndrome coronavirus-2). It should be remembered that in the
desert southwest of the United States, we have an ongoing epidemic of coccidioidomycosis
(CM). There are additionally many other respiratory illnesses that could be confused with
CoV-2 or overlooked. This is a case report of CoV-2 engrafted on chronic cavitary
pulmonary CM. In a time where the coronavirus pandemic is becoming rampant, we demonstrate
the case of a coinfection with cavitary pulmonary CM. In this case, the importance of
detection of the coronavirus and treatment of the coinfection is explored.</p></abstract><kwd-group><kwd>pulmonary coccidioidomycosis</kwd><kwd>cavitary coccidioidomycosis</kwd><kwd>CoV-2</kwd><kwd>SARS-Cov-2</kwd><kwd>corona virus</kwd><kwd>COVID19</kwd><kwd>pneumonia</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2020</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-2324709620930540"><title>Introduction</title><p>CoV-2 (coronavirus-2) is a worldwide pandemic with variable severity. Inevitably, the high
frequency of this disease will coexist in individuals with many other disease entities. We
recognize that individuals with chronic comorbidities such as chronic obstructive pulmonary
disease and heart failure have increased morbidity and mortality from CoV-2 infection. It
has been noted that patients with CoV-2 may be coinfected with influenza and other
respiratory viruses.<sup><xref rid="bibr1-2324709620930540" ref-type="bibr">1</xref></sup> Bacterial superinfection, apparently less common than in influenza, has also been
reported.<sup><xref rid="bibr2-2324709620930540" ref-type="bibr">2</xref>,<xref rid="bibr3-2324709620930540" ref-type="bibr">3</xref></sup></p><p>Coccidioidomycosis (CM) is an endemic dimorphic fungus whose frequency in the southwest
United States in recent years is epidemic.<sup><xref rid="bibr3-2324709620930540" ref-type="bibr">3</xref></sup> The California Department of Public Health annual report for 2018 demonstrates a
significant increase in CM cases since 2015. The reason for this increase remains unclear.<sup><xref rid="bibr4-2324709620930540" ref-type="bibr">4</xref></sup> The case rate as demonstrated in <xref ref-type="fig" rid="fig1-2324709620930540">Figure 1</xref> would indicate the CM is epidemic in California. There are similar data
for Arizona (see <xref ref-type="fig" rid="fig1-2324709620930540">Figure 1</xref>).</p><fig id="fig1-2324709620930540" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Coccidioidomycosis and incidence rates by year of estimated illness onset, California,
2001 to 2018.<sup><xref rid="bibr4-2324709620930540" ref-type="bibr">4</xref></sup></p></caption><graphic xlink:href="10.1177_2324709620930540-fig1"/></fig><p>It is inevitable that CoV-2 and CM will be found to coexist in individual patients. A
variety of clinical scenarios are possible. Most probable would be a person who contracts
pulmonary CM and subsequently develops CoV-2. It is noteworthy that the symptoms of the 2
diseases are extraordinarily similar and include fever, dry cough, dyspnea, myalgia, and
headache.<sup><xref rid="bibr3-2324709620930540" ref-type="bibr">3</xref>,<xref rid="bibr5-2324709620930540" ref-type="bibr">5</xref>,<xref rid="bibr6-2324709620930540" ref-type="bibr">6</xref></sup></p><p>Radiographic changes may mimic each other at the margin. Less common will be new CoV-2
infection in individuals with chronic pulmonary CM disease, such as in our case.</p><p>CoV-2 may also complicate patients with protracted disseminated disease or primary
infection with persistent inflammatory changes (ie, elevated C-reactive protein). Certainly,
CoV-2 will occur in CM patients who have largely or entirely resolved their illness.</p></sec><sec sec-type="methods" id="section2-2324709620930540"><title>Methods</title><p>Expedited Kern Medical Institutional Review Board approval. Review of the patient&#x02019;s
record.</p></sec><sec sec-type="cases" id="section3-2324709620930540"><title>Case Report</title><p>Described is a 48-year-old Hispanic male with chronic cavitary pulmonary CM nonadherent
with therapy and visits. He also had uncontrolled diabetes. He presented to his primary care
provider after having 6 days of fever, cough, and body aches. The primary care provider
diagnosed bronchitis and prescribed azithromycin.</p><p>Two days later, the patient went to Kern Medical&#x02019;s Emergency Department for weakness,
progressive cough, fever, and body aches. His vital signs and physical examinations were
unremarkable, including an oxygen saturation of 99% on room air. Complete blood count
revealed lymphopenia (absolute lymphocyte count of 1000 cells/&#x000b5;L). Inflammatory markers were
not obtained. Chemistry demonstrated a glucose of 317 mg/dL, albumin of 2.6 g/dL, and total
protein of 8.3 g/dL. Blood cultures were negative. Rapid antigen testing for influenza A and
B were negative. Chest X-ray was compared with prior imaging and revealed an increase in
size of the cavitary lesion of the right upper lobe (see <xref ref-type="fig" rid="fig2-2324709620930540">Figure 2</xref>).</p><fig id="fig2-2324709620930540" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Chest X-ray at presentation demonstrating cavitary lesion of right upper lobe.</p></caption><graphic xlink:href="10.1177_2324709620930540-fig2"/></fig><p>Computed tomography of the chest revealed ground-glass peripheral discreet infiltrates. New
ground-glass opacities were distributed peripherally in bilateral lungs<sup><xref rid="bibr7-2324709620930540" ref-type="bibr">7</xref>,<xref rid="bibr8-2324709620930540" ref-type="bibr">8</xref></sup> (see <xref ref-type="fig" rid="fig3-2324709620930540">Figure 3a</xref> and <xref ref-type="fig" rid="fig3-2324709620930540">b</xref>).</p><fig id="fig3-2324709620930540" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>(a and b) Computed tomography (CT) of the chest showed increased ground-glass opacities
in bilateral lobes. These were not seen in previous CT chest.</p></caption><graphic xlink:href="10.1177_2324709620930540-fig3"/></fig><p>Coccidioidal serologic tests were positive complement fixing antibodies, 1:32.
Nasopharyngeal swab positive for SARS (severe acute respiratory syndrome)-CoV-2.
Hospitalization and was not required and he was discharged home. The patient was called by
the emergency department physician and informed of the results. This is the first reported
case of cavitary pulmonary CM coinfection with CoV-2.</p></sec><sec sec-type="discussion" id="section4-2324709620930540"><title>Discussion</title><p>The clinical symptoms of pulmonary CM and CoV-2 infection overlap. The majority of CoV-2 is
more acute and CM has a more gradual progression of symptoms.<sup><xref rid="bibr5-2324709620930540" ref-type="bibr">5</xref></sup></p><p>Distinguishing laboratory features of CM can include an absolute eosinophil count &#x0003e;350
cells/&#x000b5;L.<sup><xref rid="bibr9-2324709620930540" ref-type="bibr">9</xref>,<xref rid="bibr10-2324709620930540" ref-type="bibr">10</xref></sup> CoV-2 patients commonly
demonstrate lymphopenia, thrombocytopenia, transaminases, and an increased ferritin level is
typical.<sup><xref rid="bibr11-2324709620930540" ref-type="bibr">11</xref>,<xref rid="bibr12-2324709620930540" ref-type="bibr">12</xref></sup> Both demonstrate elevated
inflammatory markers including C-reactive protein and erythrocyte sedimentation rate.<sup><xref rid="bibr10-2324709620930540" ref-type="bibr">10</xref></sup></p><p>The radiographic features of the disease are significantly different. The typical
radiologic manifestations of primary CM is a parenchymal process.<sup><xref rid="bibr13-2324709620930540" ref-type="bibr">13</xref></sup> The lung consolidation can be localized or multi-segmental. While usually,
unilaterally it may be bilateral and extensive. The density can vary from ground glass to
dense consolidation. The consolidation can also excavate forming thick- or thin-walled cavities.<sup><xref rid="bibr14-2324709620930540" ref-type="bibr">14</xref></sup></p><p>CM may be perihilar with evident lymphadenitis and is commonly basilar. The density can
vary from ground glass to consolidation. Cavitation is a complication of primary
CM.<sup><xref rid="bibr13-2324709620930540" ref-type="bibr">13</xref>,<xref rid="bibr14-2324709620930540" ref-type="bibr">14</xref></sup> In this case, the computed
tomography demonstrated a new infectious process superimposed on the chronic right upper
lobe cavitary lesion, leading to cavitary expansion. The multiple ground-glass opacities,
mostly peripherally located, were completely new developments for this patient.</p><p>CoV-2 typically manifests as bilateral peripheral opacification, with or without
consolidation, intralobular crazy-paving, reverse halo sign, or other manifestations of
organizing pneumonia. These findings are nonspecific and are also shared by other processes
such as other viral pneumonias, drug toxicities, and connective tissue diseases.<sup><xref rid="bibr14-2324709620930540" ref-type="bibr">14</xref></sup> The less classic the presentation, the wider the differential of diseases that will
manifest in a similar fashion. Differentiation by radiographic pattern alone is not
reliable.</p><p>Follow-up imaging has not yet been done to radiographically correlate therapeutic response
to antifungal treatment. Differences may exist in the therapeutic response of the right
upper lobe chronic cavitation as compared with the multiple ground-glass opacities. In CM,
clinical resolution of symptoms typically occurs before radiographic resolution with
antifungal therapy. Radiographic resolution may take months to years or not at all for
coccidioidal cavitary lesions. Coccidioidal ground-glass opacities are usually more acute
findings and subsequent resolution is anticipated earlier.</p><p>The odds of developing severe respiratory failure in CM are quite low. The risk for
ventilatory support is much higher in CoV-2.<sup><xref rid="bibr11-2324709620930540" ref-type="bibr">11</xref></sup></p></sec><sec sec-type="conclusions" id="section5-2324709620930540"><title>Conclusion</title><p>The coincidence of CoV-2 and CM is inevitable. This case has had a salutary outcome thus
far. Moreover, it is probable that CoV-2 coinfection on more acute pneumonic cases or those
with severe chronic pulmonary CM will have worse morbidity and mortality.<sup><xref rid="bibr1-2324709620930540" ref-type="bibr">1</xref></sup> The same may well hold true for patients with chronic disseminated disease,
particularly if they have ongoing inflammation.</p><p>The patient with stable resolved pulmonary CM without significant permanent lung injury is
not probably at risk for more severe CoV-2 than others of a similar age and comorbidity profile.<sup><xref rid="bibr7-2324709620930540" ref-type="bibr">7</xref></sup> This is also likely true for persons with stable disseminated disease without evident
inflammation whether on or off antifungal therapy. The patient described in this report has
improved from his CoV-2 infection despite active chronic coccidioidal disease with pulmonary
cavitation.</p></sec></body><back><fn-group><fn fn-type="COI-statement"><p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research,
authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p></fn><fn fn-type="other"><p><bold>Ethics Approval:</bold> Ethical approval to report this case was obtained from the Kern Medical Institutional
Review Board (Approval ID: 20020).</p></fn><fn fn-type="other"><p><bold>Informed Consent:</bold> Informed consent for patient information to be published in this article was not obtained
because the patient was lost to follow-up.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Valerie F. Civelli <inline-graphic xlink:href="10.1177_2324709620930540-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-1052-0144">https://orcid.org/0000-0002-1052-0144</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2324709620930540"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Epidemiological and clinical
characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a
descriptive study</article-title>. <source>Lancet</source>.
<year>2020</year>;<volume>395</volume>:<fpage>507</fpage>-<lpage>513</lpage>.<pub-id pub-id-type="pmid">32007143</pub-id></mixed-citation></ref><ref id="bibr2-2324709620930540"><label>2</label><mixed-citation publication-type="web">
<person-group person-group-type="author"><name><surname>Wild</surname><given-names>D</given-names></name></person-group>
<article-title>New guidelines released for managing COVI-19
patients</article-title>. Published March 26, 2020. <comment>Accessed May 14,
2020</comment>
<ext-link ext-link-type="uri" xlink:href="https://www.idse.net/Covid-19/Article/03-20/New-Guidelines-Released-for-Managing-COVID-19-Patients/57722">https://www.idse.net/Covid-19/Article/03-20/New-Guidelines-Released-for-Managing-COVID-19-Patients/57722</ext-link></mixed-citation></ref><ref id="bibr3-2324709620930540"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freedman</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>BR</given-names></name><name><surname>McCotter</surname><given-names>O</given-names></name><name><surname>Benedict</surname><given-names>K.</given-names></name></person-group>
<article-title>Coccidioidomycosis outbreaks, United States and worldwide,
1940-2015</article-title>. <source>Emerg Infect Dis</source>.
<year>2018</year>;<volume>24</volume>:<fpage>417</fpage>-<lpage>423</lpage>.<pub-id pub-id-type="pmid">29460741</pub-id></mixed-citation></ref><ref id="bibr4-2324709620930540"><label>4</label><mixed-citation publication-type="gov">
<collab>Surveillance and Statistics Section, Infectious Diseases Branch Division of
Communicable Disease Control, Center for Infectious Diseases, California Department of
Public Health</collab>. <article-title>Epidemiologic summary of coccidioidomycosis in
California, 2018</article-title>. <comment>Accessed on April 10, 2020</comment>
<ext-link ext-link-type="uri" xlink:href="https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CocciEpiSummary2018.pdf">https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CocciEpiSummary2018.pdf</ext-link></mixed-citation></ref><ref id="bibr5-2324709620930540"><label>5</label><mixed-citation publication-type="confproc">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RH</given-names></name><name><surname>Caldwell</surname><given-names>JW</given-names></name><name><surname>Welch</surname><given-names>G</given-names></name><name><surname>Einstein</surname><given-names>HE.</given-names></name></person-group>
<article-title>The great coccidioidomycosis epidemic: clinical features</article-title>.
In: <person-group person-group-type="editor"><name><surname>Einstein</surname><given-names>HE</given-names></name><name><surname>Catanzaro</surname><given-names>A</given-names></name></person-group> eds. <conf-name>Coccidioidomycosis: Proceedings of the 5th International
Conference on Coccidioidomycosis</conf-name>, <conf-loc>Stanford University</conf-loc>;
<conf-date>August 24-27, 1994</conf-date>: Centennial Conference;
<publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>National Foundation for
Infectious Diseases</publisher-name>
<year>1996</year>:<fpage>77</fpage>-<lpage>87</lpage>.</mixed-citation></ref><ref id="bibr6-2324709620930540"><label>6</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Lauer</surname><given-names>SA</given-names></name><name><surname>Grantz</surname><given-names>KH</given-names></name><name><surname>Bi</surname><given-names>Q</given-names></name></person-group>, <etal>et al</etal>
<article-title>The incubation period of coronavirus
disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and
application</article-title> [published online March 11, 2020]. <source>Ann Intern
Med</source>. doi:<pub-id pub-id-type="doi">10.7326/M20-0504</pub-id></mixed-citation></ref><ref id="bibr7-2324709620930540"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhatraju</surname><given-names>P</given-names></name><name><surname>Ghassemieh</surname><given-names>BJ</given-names></name><name><surname>Nichols</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>COVID-19 in critically ill patients in
the Seattle region&#x02014;case series</article-title> [published online March 30, 2020].
<source>N Engl J Med</source>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2004500</pub-id></mixed-citation></ref><ref id="bibr8-2324709620930540"><label>8</label><mixed-citation publication-type="web">
<collab>American College of Radiology</collab>. <article-title>ACR recommendations for the
use of chest radiography and computed tomography (CT) for suspected COVID-19
infection</article-title>. Published March 11, 2020. <comment>Accessed on March 22,
2020</comment>
<ext-link ext-link-type="uri" xlink:href="https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection">https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection</ext-link></mixed-citation></ref><ref id="bibr9-2324709620930540"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Epstein</surname><given-names>F</given-names></name><name><surname>Rothenberg</surname><given-names>M.</given-names></name></person-group>
<article-title>Eosinophilia</article-title>. <source>N Engl J Med</source>.
<year>1998</year>;<volume>338</volume>:<fpage>1592</fpage>-<lpage>1600</lpage>.<pub-id pub-id-type="pmid">9603798</pub-id></mixed-citation></ref><ref id="bibr10-2324709620930540"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galgiani</surname><given-names>JN</given-names></name><name><surname>Ampel</surname><given-names>NM</given-names></name><name><surname>Blair</surname><given-names>JE</given-names></name></person-group>, <etal>et al</etal>
<article-title>Infectious Diseases Society of America
(IDSA) clinical practice guideline for the treatment of
coccidioidomycosis</article-title>. <source>Clin Infect Dis</source>.
<year>2016</year>;<volume>63</volume>:<fpage>e112</fpage>-<lpage>e146</lpage>.<pub-id pub-id-type="pmid">27470238</pub-id></mixed-citation></ref><ref id="bibr11-2324709620930540"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McGonagle</surname><given-names>D</given-names></name><name><surname>Sharif</surname><given-names>K</given-names></name><name><surname>O&#x02019;Regan</surname><given-names>A</given-names></name><name><surname>Bridgewood</surname><given-names>C.</given-names></name></person-group>
<article-title>The role of cytokines including interleukin-6 in COVID-19 induced pneumonia
and macrophage activation syndrome-like disease</article-title>. <source>Autoimmun
Rev</source>.
<year>2020</year>;<volume>19</volume>:<fpage>102537</fpage>.<pub-id pub-id-type="pmid">32251717</pub-id></mixed-citation></ref><ref id="bibr12-2324709620930540"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name></person-group>
<article-title>Coronavirus disease 2019 (COVID-19): a clinical update</article-title>
[published online April 2, 2020]. <source>Front. Med</source>. doi:<pub-id pub-id-type="doi">10.1007/s11684-020-0767-8</pub-id></mixed-citation></ref><ref id="bibr13-2324709620930540"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jude</surname><given-names>CM</given-names></name><name><surname>Nayak</surname><given-names>NB</given-names></name><name><surname>Patel</surname><given-names>MK</given-names></name><name><surname>Deshmukh</surname><given-names>M</given-names></name><name><surname>Batra</surname><given-names>P.</given-names></name></person-group>
<article-title>Pulmonary coccidioidomycosis, pictorial review of chest radiographic and CT
findings</article-title>. <source>Radiographics</source>.
<year>2014</year>;<volume>34</volume>:<fpage>912</fpage>-<lpage>925</lpage>.<pub-id pub-id-type="pmid">25019431</pub-id></mixed-citation></ref><ref id="bibr14-2324709620930540"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simpson</surname><given-names>S</given-names></name><name><surname>Kay</surname><given-names>F</given-names></name><name><surname>Abbara</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Radiographical Society North America
Expert Censuses Statement on reporting Chest CT Findings Related to COVID
19</article-title>. Endorsed by the Society of Thoracic Radiology, the American College
of Radiology, and RSNA [published online April 28, 2020]. <source>J Thorac
Imaging</source>. doi:<pub-id pub-id-type="doi">10.1097/RTI.0000000000000524</pub-id></mixed-citation></ref></ref-list></back></article>